Interim Safety Analysis or Re-Screening [Design Issues]

posted by professionalr – India, 2025-01-09 23:56 (11 d 05:49 ago) – Posting: # 24336
Views: 302

Hi all,

We are planning to conduct a bioequivalence study for submission in Egypt. The molecules of interest necessitate a washout period of approximately three months in a crossover design. Should we perform re-screening/interim safety analysis before the dosing of Period II?

Edit: Category changed; see also this post #1. [Helmut]
—
Thanks,
RP.

Complete thread:

UA Flag
Activity
 Admin contact
23,363 posts in 4,906 threads, 1,679 registered users;
165 visitors (0 registered, 165 guests [including 13 identified bots]).
Forum time: 05:46 CET (Europe/Vienna)

The combination of some data and an aching desire
for an answer does not ensure that a reasonable answer
can be extracted from a given body of data.    John W. Tukey

The Bioequivalence and Bioavailability Forum is hosted by
BEBAC Ing. Helmut Schütz
HTML5